PHARMIGENE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19 TWD | -2.06% |
|
-2.06% | -8.21% |
| 04-30 | Pharmigene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Pharmigene, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 134M 4.15M 5.67M | Sales 2023 | 133M 4.11M 5.62M | Capitalization | 1.04B 32.37M 44.23M |
|---|---|---|---|---|---|
| Net income 2022 | -42M -1.3M -1.78M | Net income 2023 | -72M -2.23M -3.05M | EV / Sales 2022 | 5.06 x |
| Net cash position 2022 | 186M 5.77M 7.88M | Net Debt 2023 | 390M 12.09M 16.52M | EV / Sales 2023 | 10.8 x |
| P/E ratio 2022 |
-20.2
x | P/E ratio 2023 |
-12.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.29% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.06% | ||
| 1 week | -2.06% | ||
| Current month | -2.06% | ||
| 1 month | -1.04% | ||
| 3 months | -4.04% | ||
| 6 months | -17.39% | ||
| Current year | -8.21% |
1 week
18.70
19.60
1 month
18.7020.00
Current year
18.7021.10
1 year
18.7025.70
3 years
13.4027.10
5 years
13.4036.00
10 years
13.4036.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fu Hui Chan
CEO | Chief Executive Officer | - | 19-11-03 |
Kuan Chih Chen
COO | Chief Operating Officer | - | 19-11-03 |
Wu Jung Hsieh
AUD | Comptroller/Controller/Auditor | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kuan Chih Chen
COO | Chief Operating Officer | - | 19-11-03 |
Chun Chi Chiang
BRD | Director/Board Member | - | - |
Fu Hui Chan
CEO | Chief Executive Officer | - | 19-11-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 19 | -2.06% | 36,800 |
| 24-04-30 | 19.4 | +1.57% | 37,600 |
| 24-04-29 | 19.1 | -1.55% | 7,000 |
| 24-04-26 | 19.4 | -1.02% | 23,000 |
| 24-04-25 | 19.6 | 0.00% | 24,000 |
End-of-day quote Taipei Exchange, May 02, 2024
More quotes
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.21% | 29.7M | |
| -16.10% | 11.41B | |
| -30.20% | 2.3B | |
| -14.31% | 2.16B | |
| -26.03% | 1.56B | |
| +36.95% | 1.19B | |
| -2.40% | 760M | |
| -19.00% | 506M | |
| -38.57% | 444M | |
| +13.72% | 339M |
- Stock Market
- Equities
- 7595 Stock
